Greenberg R B
Am J Hosp Pharm. 1978 Jun;35(6):729-32.
Provisions of the Drug Regulation Reform Act of 1978 are discussed. Included in the discussion are drug monographs and product licenses, investigations and approvals of drugs, drug information, labeling, promotion and education, penalties, and the National Center for Clinical Pharmacology. The Act eliminates the individual NDA approach to regulation and replaces it with a system of monographs on "drug entities" and "drug product" licenses. It amplifies and redefines the investigational process to facilitate and promote research while protecting patients' rights. It also divides the commercial investigation process into two phases: drug innovation investigations and drug development investigations.
讨论了1978年《药品监管改革法案》的条款。讨论内容包括药品专论和产品许可证、药品的调查与审批、药品信息、标签、推广与教育、处罚以及国家临床药理学中心。该法案取消了对新药申请的个别监管方式,代之以关于“药品实体”和“药品产品”许可证的专论体系。它扩大并重新定义了调查程序,以促进和推动研究,同时保护患者权益。它还将商业调查程序分为两个阶段:药物创新调查和药物开发调查。